DiaMedica Therapeutics Inc. (DMAC)$5.91
Market Cap: 171.42 MCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for DiaMedica Therapeutics Inc. (DMAC).
HEALTHCARE
BIOTECHNOLOGY
DCF ready
Valuation
-5.4x
EV/FCF, N/A FCF yield
Quality
-58.4%
ROIC, N/A FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 11.8x current ratio
Superinvestors
1
Top: Leon Cooperman (0.5%)
Strengths to research
- Debt/equity looks manageable at 0.0x.
- 9 annual periods are available for trend analysis.
Watchouts
No major valuation, balance sheet, or growth watchouts were detected by the static screen.
Annual data: 9 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for DMAC.
Grade F
1
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| DMAC Target | DiaMedica Therapeutics Inc. | $171.4M | N/A | -5.4x | -58.4% | N/A | N/A | N/A | N/A | N/A |
| INBX | Inhibrx | $178.5M | -11.2x | -0.4x | -1752.2% | N/A | -9986.5% | N/A | N/A | N/A |
| CGEN | Compugen Ltd | $128.1M | 7.4x | 1.2x | 34.4% | 105.2% | 43.1% | 87.3% | -2.8x | N/A |
| COYA | Coya Therapeutics Inc | $107.2M | -3.8x | -5.6x | -49.3% | N/A | -135.2% | N/A | N/A | N/A |
| CRBU | Caribou Biosciences Inc. | $79.9M | -1.3x | -0.6x | -121.2% | -2.0% | -1006.8% | N/A | N/A | N/A |
| GUTS | Fractyl Health Inc | $79.8M | -0.5x | 0.0x | -1490.3% | N/A | N/A | N/A | N/A | N/A |
| DNA | Ginkgo Bioworks Holdings Inc. | $402.4M | -1.5x | -1.3x | -0.1% | 17.3% | -105.0% | N/A | N/A | N/A |
| ORIC | ORIC Pharmaceuticals Inc. | $405.2M | -5.7x | -3.2x | -33.7% | N/A | N/A | N/A | N/A | N/A |
| IVVD | Invivyd Inc. | $69.0M | -3.7x | 2.7x | -21.7% | N/A | -109.1% | N/A | N/A | N/A |
Financial Charts
No financial data available for DMAC (annual).
1 superinvestors own DMAC
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Leon Cooperman Leon Cooperman | 2,020,000 | $14M | 0.45% | ▲ +404.7% |